Coloplast A/S (NASDAQ:CLPBY) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Friday.

According to Zacks, “Coloplast A/S develops and provides health care products and services. Its operating business segments consist of Chronic Care, Urology Care and Wound & Skin Care. The Chronic Care segment covers the sale of ostomy care products and continence care products. The Urology Care segment offers urological products, including disposable products. The Wound and Skin Care segment covers the sale of wound and skin care products. Coloplast A/S is headquartered in Humlebaek, Denmark. “

Coloplast A/S (CLPBY) traded up 0.12% during trading on Friday, reaching $8.27. The company’s stock had a trading volume of 54,821 shares. Coloplast A/S has a 1-year low of $6.14 and a 1-year high of $8.84. The stock has a market capitalization of $17.56 billion and a PE ratio of 34.66. The stock has a 50 day moving average price of $8.35 and a 200 day moving average price of $8.11.

TRADEMARK VIOLATION NOTICE: This news story was published by American Banking News and is the sole property of of American Banking News. If you are accessing this news story on another site, it was copied illegally and reposted in violation of United States and international copyright and trademark law. The correct version of this news story can be read at https://www.americanbankingnews.com/2017/09/08/coloplast-as-clpby-rating-lowered-to-hold-at-zacks-investment-research.html.

Get a free copy of the Zacks research report on Coloplast A/S (CLPBY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Coloplast A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coloplast A/S and related companies with MarketBeat.com's FREE daily email newsletter.